Heart Failure Reviews最新文献

{"title":"Novel treatment strategies in cardiogenic shock: an update on ongoing clinical trials.","authors":"Mireia Padilla-Lopez, Francesca Manicone, Sarah L D Holle, Florian A Wenzl, Antoine Kimmoun, Alexandre Mebazaa, Alessandro Sionis","doi":"10.1007/s10741-026-10637-z","DOIUrl":"10.1007/s10741-026-10637-z","url":null,"abstract":"<p><p>The identification and management of cardiogenic shock remain significant clinical challenges, as evidenced by persistently high mortality rates and the absence of standardized therapeutic strategies. This article provides a comprehensive overview of ongoing clinical trials in the treatment of cardiogenic shock, organized into three principal approaches aimed at improving patient outcomes: novel pharmacological therapies, optimized use of mechanical circulatory support, and advanced hemodynamic monitoring strategies. By synthesizing the available evidence, we highlight current research directions and discuss how emerging data may inform future clinical practice.</p>","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":"31 1","pages":""},"PeriodicalIF":5.3,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147837188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A taste of CAVIAR: can PCSK9 inhibition slow vasculopathy progression in heart transplantation?","authors":"Kaitlyn Granstaff, Jolie Bruno, Baljash Cheema, Kaveh Hosseini, Tamas Alexy, Brett W Sperry","doi":"10.1007/s10741-026-10634-2","DOIUrl":"10.1007/s10741-026-10634-2","url":null,"abstract":"","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":"31 1","pages":""},"PeriodicalIF":5.3,"publicationDate":"2026-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147769892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Palliative care interventions and outcomes in patients with heart failure: an umbrella review.","authors":"Jane Kim, Amanda Datesman, Hunter Groninger, Silas Selorm Daniels-Donkor, Santiago Bedoya Moreno, Anirudh Rao, Kelley Anderson","doi":"10.1007/s10741-026-10632-4","DOIUrl":"10.1007/s10741-026-10632-4","url":null,"abstract":"<p><p>An expanding research base of systematic reviews has evaluated the effect of palliative care (PC) interventions delivered by primary or specialty PC providers for patients with heart failure (HF) and their caregivers. However, the overall evidence base has not been systematically examined. This umbrella review synthesizes the evidence regarding PC interventions among patients with HF to: 1) Describe interventions based on the palliative care domains in the AHA/ACC/HFSA HF guidelines, 2) Examine the effect of interventions on patient-centered and healthcare utilization outcomes, and 3) Provide recommendations for practice, policy and future research. Using the Joanna Briggs Institute methodology for umbrella reviews, we comprehensively searched for systematic reviews in MEDLINE, CINAHL, and Embase databases with no date restrictions. Published, peer-reviewed reviews were included. The search identified 19 reviews (high-quality, 11 with meta-analyses), of 104 unique primary studies after de-duplication (low to moderate quality). Primary and specialty PC was associated with improvements in quality of life, depression, advanced care planning, and reduced hospitalizations. The effect of PC on reducing symptom burden was inconclusive. Limited evidence demonstrated improvements in anxiety, satisfaction with care, caregiver burden, and hospital length of stay. PC did not significantly impact mortality rates or hospice referral. The concordance of the overall evidence was high, and although the quality of primary studies was overall low to moderate, findings confirm that primary and specialty PC offer meaningful benefits for patients with HF. Future research is required on caregiver outcomes, medically complex illness trajectories, intervention timing and fidelity, standardized outcome measurements, and longitudinal study designs with larger sample sizes.</p>","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":"31 1","pages":""},"PeriodicalIF":5.3,"publicationDate":"2026-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13106263/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147769899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Individually tailored monitoring at home after hospitalization for HEART failure (IT-HEART): design and baseline characteristics of a randomized clinical trial.","authors":"Karoline S Braanaas, Toril Dammen, Morten W Fagerland, Einar Husebye, Amund Leinaas, Henrik Schirmer, Elise Sverre, Erlend Aune, Peder L Myhre, John Munkhaugen","doi":"10.1007/s10741-026-10635-1","DOIUrl":"10.1007/s10741-026-10635-1","url":null,"abstract":"<p><p>Telemonitoring has emerged as a promising alternative to conventional heart failure (HF) management, but randomized trials show conflicting results, and data from high-risk populations with frailty, is scarce. The Individually Tailored monitoring at home after HEART failure (IT-HEART) trial evaluates whether a non-invasive multi-component telemonitoring program improves outcomes in HF patients after HF-hospitalization. The aim of this study is to describe flow of patients and baseline characteristics of the IT-HEART trial population. This multicenter, open-label, blinded-endpoint trial randomized HF patients to either written information and a standardized self-treatment plan (Control) or HF education, a personalized self-treatment plan, and three months of home telemonitoring (Intervention). The primary endpoint is the total number of HF hospitalizations or cardiovascular death. Of 1016 consecutively screened patients, 200 (19.7%) were randomized. At baseline, median age was 78 (IQR 70–83) years, and 29.5% were women. Participants were multimorbid (median 6 diagnoses) with a median Clinical Frailty Scale score 4 (IQR 4–5). Median score of the European Heart Failure Self-care Behaviour Scale was 53 (IQR 35–67), and 75.5% had inadequate self-care. Self-rated knowledge on HF management was 3 (IQR 0–7) on a 0–10 Likert scale. Only 35.5% (n = 71) weighed themselves weekly whereas 1% (n = 2) reported having a self-care plan. In conclusion, patients enrolled after a recurrent HF hospitalization were multimorbid and frail, and scored low on self‑care and health literacy. The IT-HEART intervention is targeted to these factors and has the potential to improve clinical and patient‑reported outcomes, and costs.</p>","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":"31 1","pages":""},"PeriodicalIF":5.3,"publicationDate":"2026-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13102892/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147769914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CalShock: beyond the shock team, building on California's cardiogenic shock system of care.","authors":"Fletcher M Bell, Jessica N Holtzman, Harshith P Chandrakumar, Emily P Marogi, Rola Khedraki, Richard Cheng, Andrea Elliott, Anthony A Hilliard, Dipti Itchhaporia, Meshe D Chonde, Srihari S Naidu, Glenn Egrie, Ehtisham Mahmud, Jeffrey M Tyler, David A Morrow, Antoine Sakr, Paul Marano, Joseph L Thomas, Krishnan Soni, Lundy Campbell, Alyssa Klein, Aditya S Bharadwaj, Connor G O'Brien","doi":"10.1007/s10741-026-10628-0","DOIUrl":"10.1007/s10741-026-10628-0","url":null,"abstract":"<p><p>Regional cardiogenic shock (CS) response systems are strong in concept but remain inconsistently implemented in the United States, with persistent heterogeneity in shock classification, mechanical circulatory support (MCS) deployment, hemodynamic monitoring, and transfer pathways. In California, these challenges are magnified by geography and fragmented hospital networks. The inaugural CALShock conference, convened in Los Angeles in February 2025 by the California Chapter of the American College of Cardiology, brought together multidisciplinary experts to synthesize emerging evidence and operational strategies for scalable improvements to shock systems of care. Key themes included routine use of shared classification and phenotyping frameworks, streamlined shock team activation and escalation workflows, transport as essential infrastructure, standardized prevention and management of MCS-related complications with clear exit strategies, broader registry participation, and integration of survivorship and post-discharge planning into comprehensive shock care. We describe the conference framework as a replicable model for other states and regions seeking to advance cardiogenic shock systems of care.</p>","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":"31 1","pages":""},"PeriodicalIF":5.3,"publicationDate":"2026-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147769855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Digital heart failure management: Insights from the COPILOT study.","authors":"Jonas M Rolland, Tarjei Øvrebotten, Kevin Damman, Stephen J Greene, Peder L Myhre","doi":"10.1007/s10741-026-10633-3","DOIUrl":"10.1007/s10741-026-10633-3","url":null,"abstract":"<p><p>Suboptimal implementation of guideline-directed medical therapy (GDMT) remains a major problem in heart failure (HF) care. The Cooperative Program for Implementation of Optimal Therapy in Heart Failure (COPILOT-HF) trial evaluated an innovative remote strategy to optimize GDMT across the spectrum of HF, irrespective of left ventricular ejection fraction (LVEF). This pragmatic randomized study compared a pharmacist-led, navigator-assisted remote program against traditional provider notification and education. The results, recently presented at the American Heart Association 2025 Scientific Sessions, offer compelling insights into overcoming clinical inertia and improving HF management in the digital age. This mini review examines the trial’s key findings and their potential to reshape HF care delivery.</p>","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":"31 1","pages":""},"PeriodicalIF":5.3,"publicationDate":"2026-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13091802/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147716632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Voice recognition as an innovative method to identify and monitor heart failure - a review.","authors":"Amy S Fuller, Nduka C Okwose, Sarah J Charman, Alban E Voppel, Renae J Stefanetti, Amy Groenewegen, Annamaria Del Franco, Maria Tafelmeier, Andrej Preveden, Aleksandra Milovancev, Duncan Edwards, Anne P Nelissen, Fausto Barlocco, Alessandra Fornaro, Jose Luis Zamorano, Massimo Milli, Laura Sasso, Giulia Taborchi, Simone Bartolini, Serena Fatucchi, Prithwish Banerjee, Guy A MacGowan, Oscar Fernandez, Marta Jimenez-Blanco Bravo, Lars S Maier, Iacopo Olivotto, Frans H Rutten, Jonathan Mant, Lazar Velicki, Petar M Seferovic, Nenad Filipovic, Djordje G Jakovljevic","doi":"10.1007/s10741-026-10625-3","DOIUrl":"10.1007/s10741-026-10625-3","url":null,"abstract":"<p><p>Screening of heart failure (HF) remains suboptimal. However, vocal biomarkers are an emerging tool to screen for HF and predict adverse outcomes. This article is a literature review of the current evidence, exploring the use of vocal biomarkers to screen for HF and predict hospitalisation and mortality. Voice may be utilised as a time-efficient method for the screening of HF, risk stratification, and monitoring of disease progression. Vocal biomarkers such as pause ratio and artificial neural networks can screen for HF accurately in a case-control setting. Other vocal markers like maximum phonation time, creak percent are useful to monitor disease progression. Vocal biomarkers appear to match current predictors of one-year mortality, HF related decompensation and hospitalisation. The integration of vocal biomarkers assessment in HF healthcare is promising across primary and secondary care settings. Key challenges including health data protection, regulatory compliance, and user acceptance must be addressed before these tools can be fully integrated into HF clinical care pathway.</p>","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":"31 1","pages":""},"PeriodicalIF":5.3,"publicationDate":"2026-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13086659/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147698752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prospective Austrian hypertrophic cardiomyopathy registry - design, methods and results of the run-in period.","authors":"Viktoria Santner, Christina Granitz, Martin R Grübler, Daniel Dalos, Christian Reiter, Marc-Michael Zaruba, Johann Auer, Deddo Moertl, Anna Rab, Peter P Rainer, Gert Waltl, Christian Ebner, Thomas Weber, Diana Bonderman, Stephan Dobner, Hannah Tuppinger, Viktoria Höller, Nora Schwegel, Klemens Ablasser, Andreas Zirlik, Amelie Graf, Sarah Gharibeh, Johannes Lanzerstorfer, Katharina Wörgötter, Christopher Mann, Shehroz Masood, Christy Meledeth, Clemens Steinwender, Andre Logtenberg, Moritz Messner, Carina Primus, Pia Auersperg, Lydia Mackova, Christof Baurecht, Susanne Winkler, Stephanie Schneiderbauer-Porod, Kathrin Danninger, Silvia Charwat-Resl, Paul Harbich, Rene Krenn, Nicolas Verheyen","doi":"10.1007/s10741-026-10630-6","DOIUrl":"10.1007/s10741-026-10630-6","url":null,"abstract":"<p><p>The diagnosis and management of hypertrophic cardiomyopathy (HCM) is increasingly complex, and systematic evidence remains sparse. The Austrian HCM registry aims to provide representative real-world data addressing gaps in evidence. Here, we report design, methods and results after one year enrolment. The Austrian HCM Registry is an ongoing prospective, multicenter registry including University and community hospitals across Austria. Patients with written informed consent undergo a structured assessment of symptoms, past medical history, family history and the presence of HCM-specific red flags. Clinical data derived from electrocardiogram, echocardiography, laboratory analysis, and genetic testing are collected and entered into a web-based, responsive electronic case report form. Bilateral data transfer agreements ensure legal protection of each site. Between March 2024 and May 2025, 7 University centers and 7 community hospitals from 6 out of 9 Austrian federal states were initiated. Overall, recruitment rate was 2.5 patients per site and month, with University centers and community hospitals contributing 92% and 8%. Among 303 enrolled participants, median age was 60 (25th, 75th percentile; 50, 68), 44% were women. Echocardiography, cardiac magnetic resonance imaging and genetic testing were available in 99%, 86% and 60%, respectively. In this first year, participating sites of the Austrian HCM Registry achieved a consistent and fast recruitment rate. Data availability is high and cohort characteristics align well with other registries. The Austrian HCM Registry will serve as a robust research platform providing contemporary real-world data on epidemiology, diagnosis and management of HCM in a Central European country. ClinicalTrials.gov identifier. NCT06368518.</p>","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":"31 1","pages":""},"PeriodicalIF":5.3,"publicationDate":"2026-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13083411/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147689783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tirzepatide versus dulaglutide in heart failure: another SURPASS attempt yielding a tie.","authors":"Matteo Busti, Mario Enrico Canonico, Kalliopi Keramida, Alberto Palazzuoli, Eri Kato, Yasuhiko Sakata, Tamas Alexy, Avishay Grupper, Savina Nodari, Dike B Ojji, Aaron L Sverdlov, Patricia O Guimaraes, Francesca Musella, Andrew P Ambrosy, Nicolas Girerd, Luca Monzo","doi":"10.1007/s10741-026-10627-1","DOIUrl":"10.1007/s10741-026-10627-1","url":null,"abstract":"<p><p>Heart failure (HF) is a major driver of morbidity in individuals with type 2 diabetes (T2D). While incretin-based therapies consistently reduce atherosclerotic cardiovascular (CV) events, their impact on HF outcomes remains uncertain. The SURPASS-CVOT (Comparison of tirzepatide and dulaglutide on major adverse CV events in participants with T2D and atherosclerotic disease), the first CV outcome trial directly comparing the dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists receptor agonist (GIP/GLP-1 RAs) tirzepatide with the selective GLP-1 RA dulaglutide, demonstrated noninferiority of tirzepatide for 3-point major adverse CV events (MACE), with greater metabolic and renal benefits. In the prespecified HF subgroup (20% of the trial population, defined according to investigator-reported medical history), tirzepatide reproduced the larger metabolic and renal benefits observed in the overall cohort, including greater weight loss, superior glycemic control, and a slower decline in renal function compared with dulaglutide, with similar effects in participants with and without HF. Tirzepatide was non inferior to dulaglutide for 3-point MACE irrespective of HF history. No differences were observed between treatment groups for composite HF endpoints (all-cause death or HF events; CV death or HF events) or HF events alone, both in participants with and without HF. However, as the trial was not powered for comparisons within the HF subgroup and HF endpoints were not included in the multiplicity-controlled testing hierarchy, these findings should be considered exploratory. This meeting report critically examines the SURPASS-CVOT HF subanalysis and place its results within the broader evidence on incretin-based therapies in patients with HF.</p>","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":"31 1","pages":""},"PeriodicalIF":5.3,"publicationDate":"2026-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147689781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"International Utah cardiac recovery symposium (U-CARS) 2025:translational and basic science proceedings.","authors":"Joseph R Visker, Eleni Tseliou, Konstantinos Drosatos, Omar Wever-Pinzon, William Holland, Stavros G Drakos","doi":"10.1007/s10741-026-10626-2","DOIUrl":"10.1007/s10741-026-10626-2","url":null,"abstract":"<p><p>The 13th Annual Utah Cardiac Recovery Symposium (U-CARS) brought together experts from around the globe to discuss advances in cardiac research, with an emphasis on the role of adrenergic receptors in heart disease and the use of β-blockers. Presentations highlighted new insights into β-adrenergic signaling, revealing how precise modulation of these pathways could enhance therapeutic outcomes and reduce adverse effects in heart failure (HF). Dr. Michael Bristow offered a comprehensive review of three decades of gene expression studies in the human heart. His talk highlighted how molecular profiles of β-adrenergic receptor subtypes evolve during disease progression and respond to pharmacological intervention. By outlining shifts in adrenergic receptors, along with related signaling pathways, Dr. Bristow emphasized opportunities for developing more targeted β -blocker strategies. These refined approaches along with guideline directed medical therapies could optimize patient outcomes by leveraging the intricate interplay between gene expression changes and receptor pharmacology. Next, studies were presented to understand how cells within the heart communicate with one another and with other organ systems to maintain cardiovascular homeostasis. Presenters described emerging data on signaling crosstalk between cardiomyocytes and non-myocyte cell populations, such as fibroblasts and immune cells that shape cardiac remodeling. These findings suggest that targeted manipulation of intercellular communication may protect the heart from stress-induced damage. The final series of molecular discussions explored the expanding view of HF as a multisystem syndrome that involves complex interactions between cardiovascular, renal, and metabolic processes. Research was focused on how aberrant molecular signals not only drive disease within the heart but also affect kidney function and systemic metabolism, further exacerbating HF progression. Speakers highlighted the clinical potential of integrated therapeutic strategies that use approaches to target the heart alongside renal and metabolic pathways. Synergistic approaches could better address the root causes of acute and chronic HF, slowing or reversing disease progression by restoring balanced interorgan communication.</p>","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":"31 1","pages":""},"PeriodicalIF":5.3,"publicationDate":"2026-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13202620/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147672460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}